Colorectal Cancer Articles | Page 3

TAS-102 Improves Survival in Asian mCRC Patients
TAS-102 improved overall survival compared with placebo in previously treated Asian patients with metastatic colorectal cancer (mCRC).
Marshall Recaps Milestones in CRC Paradigm
John L. Marshall, MD, recaps some of the biggest CRC advancements of 2017, and explains what those successes mean for the treatment paradigm moving forward.
Liver-Directed Therapy Shows Improvement in mCRC
Nancy E. Kemeny, MD, discusses the combination of pump and systemic therapy as a liver-directed treatment option for patients with metastatic colorectal cancer.
Questions Remain on Optimal mCRC Treatment
Leonard Saltz, MD, discusses current go-to therapies and overarching questions for mCRC treatment.
Surgery a Mainstay in Colorectal Cancer Treatment
William R. Jarnagin, MD, discusses the necessary role of surgery and novel techniques in patients with colorectal cancer.
Expert Says Clinical Trials Are Essential for Progress in Metastatic CRC
Shubham Pant, MD, stresses the importance of clinical trials as an avenue to establish more novel treatment decisions in colorectal cancer. 
Solving the BRAF Mystery in CRC: Genomic Clues Lead to Triplets and Immunotherapy
Mutations in the BRAF kinase are found in a relatively small number of patients with metastatic colorectal cancer, but they nonetheless have important implications for prognosis and response to standard therapy.
Tanios Bekaii-Saab, MD, FACP, and Rona D. Yaeger, MD, discuss the current treatment landscape and other key issues relating to this distinct subset of colorectal cancer.
A. David McCollum, MD, discusses the optimal management of CRC in the first-line setting and the ongoing research with checkpoint inhibitors designed to benefit larger groups of patients.
Efforts Continue to Expand Immunotherapy in CRC
Johanna Bendell, MD, discusses the current and emerging treatment landscape of immunotherapy for patients with CRC.
Publication Bottom Border
Border Publication
x